Poolbeg Pharma receives initial results from human challenge clinical study

Digital Asset Direct by Poolbeg Pharma PLC

London, UK | December 12, 2022 06:59 AM Eastern Standard Time

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after receiving the initial results from its LPS human challenge clinical study for its molecule POLB 001, that he hopes will eventually help in treating severe influenza. Skillington says that there were "no severe adverse events" reported among the 36 healthy volunteers.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Why News Direct

For Public Relations For Investor Relations Testimonials

About us Features News Hub

Resources

Press Blog

Why News Direct For Public Relations For Investor Relations Testimonials

What We Offer Collaborative Content Studio Advanced News Release Capability Standalone Multimedia Distribution Industry-Leading Security Unsurpassed Global Reach Actionable Analytics Synergistic PR Solutions

Pricing About us News Hub

Resources Blog Press